companydata.dkcompanydata.dk

Novo Nordisk Pharmatech A/S: Financial statements 2015

CVR: 13246149

Source: annual report 2015, Danish Business Authority

01/01/2015 – 31/12/2015

Novo Nordisk Pharmatech A/S (CVR 13246149) has filed annual accounts for 2015. In 2015, the company reported revenue of DKK 505,233,000 and a net result of DKK 92,104,000 compared with DKK 55,343,000 the year before. That is an increase of 2% compared with the year before. The profit margin was 18.2%. Equity in the 2015 report amounted to DKK 400,921,000. The solvency ratio was 64.8%. The company had 150 employees in the financial year.

Revenue
DKK 505,233,000
Gross Profit
DKK 228,049,000
Profit/Loss
DKK 92,104,000
Equity
DKK 400,921,000
Total Assets
DKK 618,589,000
Employees
150

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015505.2M228M92.1M400.9M150
2014495.2M176.6M55.3M336.8M150
2013498M170.7M46.7M304.5M141

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is Novo Nordisk Pharmatech A/S?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2015

Lene Due Svensson leaves the board of Novo Nordisk Pharmatech A/SSep 24, 2015

As of September 24, 2015, Lene Due Svensson has left the board of directors of Novo Nordisk Pharmatech A/S.

FEF CHEMICALS A/S changes name to Novo Nordisk Pharmatech A/SAug 28, 2015

On August 28, 2015, the company changed its name from FEF CHEMICALS A/S to Novo Nordisk Pharmatech A/S.

Novo Nordisk Pharmatech A/S: The 2014 annual report is outJan 29, 2015

Novo Nordisk Pharmatech A/S has published its annual report for 2014. Revenue came to DKK 495,202,000, and the net result was DKK 55,343,000.

Michael Fugl Hallgren joins the board of Novo Nordisk Pharmatech A/SJan 23, 2015

As of January 23, 2015, Michael Fugl Hallgren has joined the board of directors of Novo Nordisk Pharmatech A/S.

Henrik Ehlers Wulff joins the board of Novo Nordisk Pharmatech A/SJan 23, 2015

As of January 23, 2015, Henrik Ehlers Wulff has joined the board of directors of Novo Nordisk Pharmatech A/S.

Per Toft Valstorp leaves the board of Novo Nordisk Pharmatech A/SJan 23, 2015

As of January 23, 2015, Per Toft Valstorp has left the board of directors of Novo Nordisk Pharmatech A/S.

Jan Hoff leaves the board of Novo Nordisk Pharmatech A/SJan 23, 2015

As of January 23, 2015, Jan Hoff has left the board of directors of Novo Nordisk Pharmatech A/S.

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 489 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.

Source: annual report 2025, Danish Business Authority